Government · 1 deal
Canberra, ACT
Every published round Biomedical Translation Fund took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Denteric | Series A | 26 Sep 2019 | $14m | Lead | Startup Daily (Fri 4 Oct 2019), @AuManufacturing, Brandon BioCatalyst portfolio, Brandon Capital portfolio, Startup Daily (Thu 26 Sep 2019), denteric.com (undated), denteric.com (undated), Brandon Capital portfolio |
Companies Biomedical Translation Fund has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Denteric | 26 Sep 2019, Series A | 1 | 1 |
Fund closes reported for Biomedical Translation Fund, as distinct from the investments it has made.
Companies Biomedical Translation Fund has backed that another company then bought. An exit for the holding, not a deal Biomedical Translation Fund did.
Stories naming Biomedical Translation Fund. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.
US regulators cleared first-in-human testing of BiVACOR's total artificial heart; the OneVentures page also links earlier coverage and the Biomedical Translation Fund's investment in the device.
Brisbane immunology company Kira Biotech has launched with a $20 million Series A, OneVentures leading alongside IP Group and Queensland government support, to progress its lead antibody KB312 into early human studies.
A biotech spin-out from the University of Melbourne has raised a Series A to develop a gum disease vaccine, backed by a biomedical translation fund, a large biotech company and the university itself.
Also Brandon BioCatalyst portfolio·Startup Daily·denteric.com·denteric.com·@AuManufacturing·Startup Daily
OneVentures appoints Jim Scopa and Dan Baker to its healthcare investment team, and recalls its Healthcare Fund III backing Blade Therapeutics and BiVACOR.
The industry minister announced Biomedical Translation Fund backing: Brandon Capital invested $20 million in Respirion, OneVentures $4 million in Madorra, and $17.2 million went to an unnamed anti-fibrosis drug company.